David Brosh

The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations

Donald S. Silverberg, Dov Wexler, Miriam Blum et al. · Journal of the American College of Cardiology · 2000 · 726 citations

Anemia, Subcutaneous Erythropoietin, Heart Failure +12

Main Risk Factors for Nephropathy in Type 2 Diabetes Mellitus Are Plasma Cholesterol Levels, Mean Blood Pressure, and Hyperglycemia

Mordchai Ravid, David Brosh, D Ravid-Safran et al. · Archives of Internal Medicine · 1998 · 451 citations · Full text

Effect of No-Reflow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction on Six-Month Mortality

David Brosh, Abid Assali, Aviv Mager et al. · The American Journal of Cardiology · 2006 · 215 citations

Thrombosis, Percutaneous Coronary Intervention, Cardiovascular Disease +8

Comparison of the Predictive Value of Four Different Risk Scores for Outcomes of Patients With ST-Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Eli I. Lev, Ran Kornowski, Hana Vaknin‐Assa et al. · The American Journal of Cardiology · 2008 · 126 citations

Percutaneous Coronary Intervention, Epidemiology, Cardiovascular Disease +11

Mild renal insufficiency is associated with reduced coronary flow in patients with non-obstructive coronary artery disease

Alejandro Chade, David Brosh, Stuart T. Higano et al. · Kidney International · 2006 · 109 citations · Full text

Hemodialysis, Urology, Renal Function +10